Sage claims another big win on a small study, this time for postpartum depression
Shares of Sage Therapeutics $SAGE rocketed up 38% this morning after the Cambridge, MA-based biotech posted remarkable data from a small study of its lead drug for postpartum depression.
So far, Sage has concentrated much of its attention touting the impact of SAGE-547 on rare cases of protracted seizures called super-refractory status epilepticus. But CEO Jeff Jonas has also been pursuing a theory that the drug can have an impact on mood disorders like depression, a tough field that has seen a series of painful pratfalls by developers over the years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.